NICE recommends new treatment for breast and bowel cancer
BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7400.1166-d (Published 29 May 2003) Cite this as: BMJ 2003;326:1166
- Susan Mayor
- London
The National Institute for Clinical Excellence (NICE) has, in guidance issued last week, recommended capecitabine as the second line treatment for metastatic or locally advanced breast cancer.
Capecitabine and another antimetabolite, tegafur with uracil, have been recommended as options for the first line treatment of metastatic bowel cancer. NICE recommends capecitabine in combination with docetaxel for metastatic or locally advanced breast cancer when anthracycline based treatment has failed or is unsuitable.
A committee that included NHS healthcare professionals and lay people reviewed …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.